Global estimates on the number of persons across the Alzheimer's disease continuum

Anders Gustavsson(Karolinska Institutet), Nicholas Norton(Quantify Research (Sweden)), Thomas N. Fast(Quantify Research (Sweden)), Lutz Frölich(Heidelberg University), Jean Georges(Alzheimer Europe), Drew Holzapfel(Alzheimer’s Disease Neuroimaging Initiative), Tunahan Kirabali(Biogen (Switzerland)), Pierre Krolak‐Salmon(Université Claude Bernard Lyon 1), Paolo Maria Rossini(Università Cattolica del Sacro Cuore), Maria Teresa Ferretti(Women's Brain Project), Lydia Lanman(Roche (Switzerland)), Antonella Santuccione Chadha(Biogen (Switzerland)), Wiesje M. van der Flier(Amsterdam Neuroscience)
Alzheimer s & Dementia
June 2, 2022
10.1002/alz.12694
Cited by 812Open Access
Full Text

Abstract

INTRODUCTION: Global estimates on numbers of persons in early stages of Alzheimer's disease (AD), including prodromal and preclinical, are lacking, yet are needed to inform policy decisions on preventive measures and planning for future therapies targeting AD pathology. METHODS: We synthesized the literature on prevalence across the AD continuum and derived a model estimating the number of persons, stratified by 5-year age groups, sex, and disease stage (AD dementia, prodromal AD, and preclinical AD). RESULTS: The global number of persons with AD dementia, prodromal AD, and preclinical AD were estimated at 32, 69, and 315 million, respectively. Together they constituted 416 million across the AD continuum, or 22% of all persons aged 50 and above. DISCUSSION: Considering predementia stages, the number of persons with AD is much larger than conveyed in available literature. Our estimates are uncertain, especially for predementia stages in low- and middle-income regions where biomarker studies are missing.

Related Papers

No related papers found

Powered by citation graph analysis